GLEEVEC (IMATINIB): A BREAKTHROUGH IN CANCER TREATMENT

Journal Title: Journal of Biomedical and Pharmaceutical Research - Year 2016, Vol 5, Issue 6

Abstract

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach to management of various cancers and represents a therapeutic breakthrough. Imatinib was one of the first cancer therapies to show the potential for such targeted action. Imatinib, an oral targeted therapy, inhibits tyrosine kinases specifically BCR-ABL, c-KIT, and PDGFRA. Apart from its remarkable success in CML and GIST, Imatinib benefits various other tumors caused by Imatinib-specific abnormalities of PDGFR and c-KIT. Imatinib has also been proven to be effective in steroid-refractory chronic graft-versus-host disease because of its anti-PDGFR action. Gleevec has been approved for the treatment of patients with positive inoperable and/or metastatic malignant gastrointestinal stromal tumors (GISTs). Gleevec is a signal transduction inhibitor that works by targeting the activity of enzymes called tyrosine kinases. The activity of one of these tyrosine kinases, known as c-kit, is thought to drive the growth and division of most GISTs. Key words: CML, GIST, PDGFRA

Authors and Affiliations

Sakshi Minocha

Keywords

Related Articles

Preliminary Phyto-chemical screening of Abelmoschusesculentus Linn.

Herbal drugs with little or no adverse effects are becoming a necessity in our daily life. The herbal products & herbal drug extracts are now a day’s being used extensively for the preparation of pharmaceutical dosage fo...

EFFECT OF LACTATE DEHYDROGENASE (LDH) IN PREECLAMPSIA OF PREGANANY

Preeclampsia is responsible for significant maternal and perinatal mortality worldwide. Lactate dehydrogenase (LDH) is a multifaceted enzyme whose effects in pregnancy related complications e.g., preeclampsia (PE) is now...

Application of omics in personalized oral health care: A paradigm shift

Periodontal disease and Dental caries are the most common oral diseases in adult populations worldwide and is a major public health concern due to its substantial cost to the oral health care system. During recent years...

FORMULATION AND EVALUATION OF NASAL IN SITU GEL OF RIZATRIPTAN BENZOATE

In situ gel drug delivery systems are in elucidation form prior to supervision but once administered, endure gelation in situ, to form a gel. In the current revise nasal in situ gel of rizatriptan Benzoate was primed for...

Gene expression and sequencing techniques of transcriptome to elucidate novel function for phospholipase (s) enzyme

Sequencing of RNA, or RNA-Seq, is now a common method to analyze gene expression and to uncover novel RNA species. Aspects of RNA biogenesis and metabolism can be evaluated with specialized methods for cDNA library prepa...

Download PDF file
  • EP ID EP418080
  • DOI -
  • Views 126
  • Downloads 0

How To Cite

Sakshi Minocha (2016). GLEEVEC (IMATINIB): A BREAKTHROUGH IN CANCER TREATMENT. Journal of Biomedical and Pharmaceutical Research, 5(6), 137-152. https://europub.co.uk./articles/-A-418080